GSK reports positive RSV vaccine data
Primary endpoints were met and no side effects were reported in a trial of GSK’s RSV vaccine.
by marketwire, translated by catherine brett
GSK, formerly Glaxosmithkline, has reported positive data from its RSV vaccine trial, Bloomberg News reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
RSV caused more than 100,000 child mortalities in 2019
For subscribers
Pfizer to acquire Reviral as RSV race continues
For subscribers
